Mersana Therapeutics to be Sold to Day One Biopharmaceuticals for Up to $55.25 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Should l Buy ?
Source: PRnewswire
- Transaction Overview: Mersana Therapeutics is proposing a sale to Day One Biopharmaceuticals for $25.00 in cash per share plus a non-tradable contingent value right (CVR) potentially worth up to $30.25, totaling up to $55.25 per share, indicating a significant valuation consideration for the company.
- Legal Investigation: Former Louisiana Attorney General Charles C. Foti, Jr. is investigating whether the proposed transaction adequately reflects Mersana's true value, which could impact shareholder rights and interests.
- Shareholder Rights Protection: Kahn Swick & Foti, LLC is urging shareholders who believe the transaction undervalues the company to reach out for discussions on their legal rights, highlighting a commitment to protecting shareholder interests.
- Transaction Structure: The deal is structured as a tender offer, emphasizing time sensitivity that may affect shareholder decisions and the smooth execution of the transaction.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
